Approval and access to caner drugs - U.S. Food and Drug Administration

被引：0
|
作者：
Pazdur, Richard [1 ]
Williams, Grant [1 ]
Johnson, John [1 ]
Farrell, Ann [1 ]
Dagher, Ramzi [1 ]
机构：
[1] US FDA, Rockville, MD 20857 USA
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9 / 9
页数：1
相关论文
共 50 条
  • [31] Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs
    Fang Wu
    Heta Shah
    Min Li
    Peng Duan
    Ping Zhao
    Sandra Suarez
    Kimberly Raines
    Yang Zhao
    Meng Wang
    Ho-pi Lin
    John Duan
    Lawrence Yu
    Paul Seo
    [J]. The AAPS Journal, 23
  • [32] The U.S. medical device industry: Entrepreneurs' future hinges on reforms at the food and drug administration
    Kimbell, JJ
    [J]. FOOD AND DRUG LAW JOURNAL, 1996, 51 (02): : 339 - 343
  • [33] Residential Food Scraps Collection Access In The U.S. — The Programs
    Goldstein, Nora
    [J]. BioCycle, 2021, 62 (11)
  • [34] Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary
    Ning, Yangmin M.
    Pierce, William
    Maher, V. Ellen
    Karuri, Stella
    Tang, Sheng-Hui
    Chiu, Haw-Jyh
    Palmby, Todd
    Zirkelbach, Jeanne Fourie
    Marathe, Dhananjay
    Mehrotra, Nitin
    Liu, Qi
    Ghosh, Debasis
    Cottrell, Christy L.
    Leighton, John
    Sridhara, Rajeshwari
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6067 - 6073
  • [35] NASH: regulatory considerations for clinical drug development and U.S. FDA approval
    Brian E. Harvey
    [J]. Acta Pharmacologica Sinica, 2022, 43 : 1210 - 1214
  • [36] THE FOOD-AND-DRUG-ADMINISTRATION DRUG APPROVAL PROCESS
    AHART, GJ
    [J]. CONNECTICUT MEDICINE, 1980, 44 (03) : 161 - 166
  • [37] The Food and Drug Administration's early access and fast-track approval initiatives: How have they worked?
    Shulman, SR
    Brown, JS
    [J]. FOOD AND DRUG LAW JOURNAL, 1995, 50 (04) : 503 - 531
  • [38] U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
    de Claro, R. Angelo
    McGinn, Karen
    Kwitkowski, Virginia
    Bullock, Julie
    Khandelwal, Aakanksha
    Habtemariam, Bahru
    Ouyang, Yanli
    Saber, Haleh
    Lee, Kyung
    Koti, Kallappa
    Rothmann, Mark
    Shapiro, Marjorie
    Borrego, Francisco
    Clouse, Kathleen
    Chen, Xiao Hong
    Brown, Janice
    Akinsanya, Lara
    Kane, Robert
    Kaminskas, Edvardas
    Farrell, Ann
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (21) : 5845 - 5849
  • [39] Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs
    Kim, Chul
    Prasad, Vinay
    [J]. MAYO CLINIC PROCEEDINGS, 2016, 91 (06) : 713 - 725
  • [40] Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: Treatments in urologic oncology
    Ning, Yang-Min
    Maher, V. Ellen
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (03) : 137 - 142
12345